QR-Code

Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review

Abstract Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by intense itching, redness, and eczema. It significantly impacts the quality of life of affected individuals, often requiring long-term management strategies. Abrocitinib, an oral Janus kinase 1 (JAK1) inhibitor,...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Jonathan I. Silverberg, Eric Simpson, Melinda Gooderham, Stephan Weidinger, Melissa Watkins, Justine Alderfer
Format: Artigo
Sprache:Inglês
Veröffentlicht: Adis, Springer Healthcare 2025-12-01
Schriftenreihe:Dermatology and Therapy
Schlagworte:
Abrocitinib
Clinical practice
Flexible dosing
JAK1-selective inhibitor
Moderate-to-severe atopic dermatitis
Oral
Online-Zugang:https://doi.org/10.1007/s13555-025-01618-5
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge